Molecular imaging with theranostic nanoparticles.

Nanoparticles (NPs) offer diagnostic and therapeutic capabilities not available with small molecules or microscale tools. As the field of molecular imaging has emerged from the blending of molecular biology with medical imaging, NP imaging is increasingly common for both therapeutic and diagnostic applications. The term theranostic describes technology with concurrent and complementary diagnostic and therapeutic capabilities. Although NPs have been FDA-approved for clinical use as transport vehicles for nearly 15 years, full translation of their theranostic potential is incomplete. However, NPs have shown remarkable success in the areas of drug delivery and magnetic resonance imaging. Emerging applications include image-guided resection, optical/photoacoustic imaging in vivo, contrast-enhanced ultrasound, and thermoablative therapy. Diagnosis with NPs in molecular imaging involves the correlation of the signal with a phenotype. The location and intensity of NP signals emanating from a living subject indicate the disease area's size, stage, and biochemical signature. Therapy with NPs uses the image for resection or delivery of a small molecule or RNA therapeutic. Ablation of the affected area is also possible via heat or radioactivity. The ideal theranostic NP includes several features: (1) it selectively and rapidly accumulates in diseased tissue; (2) it reports biochemical and morphological characteristics of the area; (3) it delivers an effective therapeutic; and (4) it is safe and biodegrades with nontoxic byproducts. Such a system contains a central imaging core surrounded by small molecule therapeutics. The system targets via ligands such as IgG and is protected from immune scavengers by a cloak of protective polymer. Although no NP has achieved all of the above criteria, many NPs possess one or more of these features. While the most clinically translatable NPs have been used in the field of magnetic resonance imaging, other types in development are quickly becoming more biocompatible through methods that modify their toxicity and biodistribution profiles. In this Account, we describe diagnostic imaging and therapeutic uses of NPs. We propose and offer examples of five primary types of nanoparticles with concurrent diagnostic and therapeutic uses.

[1]  M Geso,et al.  Gold nanoparticles: a new X-ray contrast agent. , 2007, The British journal of radiology.

[2]  Zhuang Liu,et al.  Carbon nanotubes as photoacoustic molecular imaging agents in living mice. , 2008, Nature nanotechnology.

[3]  A. Cincotta,et al.  Bromocriptine – unique formulation of a dopamine agonist for the treatment of type 2 diabetes , 2010, Expert opinion on pharmacotherapy.

[4]  A. Santoro,et al.  Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  Michael J Sailor,et al.  Computationally guided photothermal tumor therapy using long-circulating gold nanorod antennas. , 2009, Cancer research.

[6]  Shelton D Caruthers,et al.  Molecular imaging of angiogenesis in early-stage atherosclerosis with alpha(v)beta3-integrin-targeted nanoparticles. , 2003, Circulation.

[7]  Betty Y. S. Kim,et al.  Current concepts: Nanomedicine , 2010 .

[8]  Arend Heerschap,et al.  Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy , 2005, Nature Biotechnology.

[9]  R Jason Stafford,et al.  Feasibility study of particle-assisted laser ablation of brain tumors in orthotopic canine model. , 2009, Cancer research.

[10]  John V Frangioni,et al.  Intraoperative sentinel lymph node mapping of the lung using near-infrared fluorescent quantum dots. , 2005, The Annals of thoracic surgery.

[11]  Chad A Mirkin,et al.  Bio-bar-code-based DNA detection with PCR-like sensitivity. , 2004, Journal of the American Chemical Society.

[12]  G. Kwon,et al.  Polymeric micelles for delivery of poorly water-soluble compounds. , 2003, Critical reviews in therapeutic drug carrier systems.

[13]  L. Zhang,et al.  Nanoparticles in Medicine: Therapeutic Applications and Developments , 2008, Clinical pharmacology and therapeutics.

[14]  M. Berger,et al.  Novel nanoliposomal CPT-11 infused by convection-enhanced delivery in intracranial tumors: pharmacology and efficacy. , 2006, Cancer research.

[15]  Mark E. Davis,et al.  Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles , 2010, Nature.

[16]  Simon R. Cherry,et al.  PET: Physics, Instrumentation, and Scanners , 2006 .

[17]  S. Gambhir,et al.  Facile synthesis, silanization, and biodistribution of biocompatible quantum dots. , 2010, Small.

[18]  Jeffrey I. Zink,et al.  Multifunctional inorganic nanoparticles for imaging, targeting, and drug delivery , 2010, BiOS.

[19]  S. Gambhir,et al.  Quantum Dots for Live Cells, in Vivo Imaging, and Diagnostics , 2005, Science.

[20]  R. Weissleder,et al.  Polymeric nanoparticle preparation that eradicates tumors. , 2005, Nano letters.

[21]  Erkki Ruoslahti,et al.  Proteolytic actuation of nanoparticle self-assembly. , 2006, Angewandte Chemie.

[22]  C. Hadjipanayis,et al.  EGFRvIII antibody-conjugated iron oxide nanoparticles for magnetic resonance imaging-guided convection-enhanced delivery and targeted therapy of glioblastoma. , 2010, Cancer research.

[23]  Xiaohua Huang,et al.  Noble metals on the nanoscale: optical and photothermal properties and some applications in imaging, sensing, biology, and medicine. , 2008, Accounts of chemical research.

[24]  T. Mihaljevic,et al.  Near-infrared fluorescent type II quantum dots for sentinel lymph node mapping , 2004, Nature Biotechnology.

[25]  Chad A Mirkin,et al.  Polyvalent DNA nanoparticle conjugates stabilize nucleic acids. , 2020, Nano letters.

[26]  V. Gebski,et al.  Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  Robert Langer,et al.  Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer. , 2007, Nano letters.

[28]  R. Stafford,et al.  Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[29]  R. Langer,et al.  Poly(ethylene oxide)-modified poly(beta-amino ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs: part 3. Therapeutic efficacy and safety studies in ovarian cancer xenograft model , 2007, Cancer Chemotherapy and Pharmacology.

[30]  Heather Kalish,et al.  Characterization of biophysical and metabolic properties of cells labeled with superparamagnetic iron oxide nanoparticles and transfection agent for cellular MR imaging. , 2003, Radiology.

[31]  Jesse V Jokerst,et al.  Affibody-functionalized gold-silica nanoparticles for Raman molecular imaging of the epidermal growth factor receptor. , 2011, Small.

[32]  D. Jaillard,et al.  Folate-conjugated iron oxide nanoparticles for solid tumor targeting as potential specific magnetic hyperthermia mediators: synthesis, physicochemical characterization, and in vitro experiments. , 2005, Bioconjugate chemistry.

[33]  Dmitri Artemov,et al.  MR molecular imaging of the Her‐2/neu receptor in breast cancer cells using targeted iron oxide nanoparticles , 2003, Magnetic resonance in medicine.

[34]  U. Schubert,et al.  Poly(ethylene glycol) in Drug Delivery: Pros and Cons as Well as Potential Alternatives. , 2011 .

[35]  R. Zare,et al.  Biodegradable nanoparticles with sustained release of functional siRNA in skin. , 2010, Journal of pharmaceutical sciences.

[36]  S. Gambhir,et al.  Molecular imaging in living subjects: seeing fundamental biological processes in a new light. , 2003, Genes & development.

[37]  Sanjiv S Gambhir,et al.  Self-illuminating quantum dot conjugates for in vivo imaging , 2006, Nature Biotechnology.

[38]  P. Ang,et al.  Phase I pharmacokinetic study of a weekly liposomal paclitaxel formulation (Genexol-PM) in patients with solid tumors. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[39]  Bert Vogelstein,et al.  The role of companion diagnostics in the development and use of mutation-targeted cancer therapies , 2006, Nature Biotechnology.

[40]  R. Schiffelers,et al.  Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. , 2004, Nucleic acids research.

[41]  Mark E. Davis,et al.  Nanoparticle therapeutics: an emerging treatment modality for cancer , 2008, Nature Reviews Drug Discovery.

[42]  Jayanth Panyam,et al.  Biodegradable nanoparticles for drug and gene delivery to cells and tissue. , 2003, Advanced drug delivery reviews.

[43]  John W. Park Liposome-based drug delivery in breast cancer treatment , 2002, Breast Cancer Research.

[44]  Zhen Cheng,et al.  Ultrasmall near-infrared non-cadmium quantum dots for in vivo tumor imaging. , 2010, Small.

[45]  M. Bawendi,et al.  Renal clearance of quantum dots , 2007, Nature Biotechnology.

[46]  Michael Hawkins,et al.  Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  M. Dewhirst,et al.  Hyperthermia enables tumor-specific nanoparticle delivery: effect of particle size. , 2000, Cancer research.

[48]  M. Natan,et al.  Glass-Coated, Analyte-Tagged Nanoparticles: A New Tagging System Based on Detection with Surface-Enhanced Raman Scattering , 2003 .

[49]  N. Barakat,et al.  Magnetically modulated nanosystems: a unique drug-delivery platform. , 2009, Nanomedicine.

[50]  A. Aigner,et al.  In vivo pharmacokinetics, tissue distribution and underlying mechanisms of various PEI(-PEG)/siRNA complexes. , 2009, Toxicology and applied pharmacology.

[51]  Jinming Gao,et al.  Theranostic nanomedicine for cancer. , 2008, Nanomedicine.

[52]  Jesse V Jokerst,et al.  Nanoparticle PEGylation for imaging and therapy. , 2011, Nanomedicine.

[53]  J Henke,et al.  Magnetofection: enhancing and targeting gene delivery by magnetic force in vitro and in vivo , 2002, Gene Therapy.

[54]  Samuel A. Wickline,et al.  Molecular Imaging of Angiogenesis in Early-Stage Atherosclerosis With &agr;v&bgr;3-Integrin–Targeted Nanoparticles , 2003 .

[55]  Ralph Weissleder,et al.  A multimodal nanoparticle for preoperative magnetic resonance imaging and intraoperative optical brain tumor delineation. , 2003, Cancer research.

[56]  Sanjiv S Gambhir,et al.  Peptide-labeled near-infrared quantum dots for imaging tumor vasculature in living subjects. , 2006, Nano letters.

[57]  Jinwoo Cheon,et al.  Artificially engineered magnetic nanoparticles for ultra-sensitive molecular imaging , 2007, Nature Medicine.

[58]  Jennifer Sturgis,et al.  Bacteria-mediated delivery of nanoparticles and cargo into cells. , 2007, Nature nanotechnology.

[59]  Bernadette Erokwu,et al.  Magnetic resonance imaging of multifunctional pluronic stabilized iron-oxide nanoparticles in tumor-bearing mice. , 2009, Biomaterials.

[60]  Erkki Ruoslahti,et al.  Targeted quantum dot conjugates for siRNA delivery. , 2007, Bioconjugate chemistry.

[61]  Volker Wagner,et al.  The emerging nanomedicine landscape , 2006, Nature Biotechnology.